Ten63 is a Duke and TTIC spin-out headquartered in the Research Triangle in North Carolina, where it is currently expanding its structural biology, biochemistry and biophysics teams. Ten63's computational team is also recruiting and has a nationwide footprint. Ten63 is leveraging its BEYOND computational platform for generative chemistry to develop first- and best-in-class therapeutics. The company is progressing an internal pipeline focused on oncology while pursuing select and strategic partnerships in multiple indications.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/03/23 | $15,900,000 | Series A |
Alexandria Venture Investments Draper Associates Hatteras Venture Partners Morpheus Ventures Sigmas Group SOSV | undisclosed |
